The indication of adjuvant chemotherapy after the resection of pancreatic cancer due to biomarkers
| Project/Area Number |
22591517
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Nagoya University |
|---|
Principal Investigator |
TAKEDA Shin 名古屋大学, 医学系研究科, 准教授 (20314015)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SUGIMOTO Hiroyuki 名古屋大学, 大学院・医学系研究科, 講師 (20437007)
FUJII Tsutomu 名古屋大学, 医学部附属病院, 助教 (60566967)
NAKAO Akimasa 名古屋大学, 大学院・医学系研究科, 助教 (70167542)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2012: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000)
Fiscal Year 2011: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2010: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | pancreatic cancer / オーダーメード医療 / 抗癌剤感受性遺伝子 / TS / DPD / adjuvant chemotherapy / S-1 / gemcitabine / OPRT / microdissection / RNA expression |
|---|
| Research Abstract |
Gemcitabine or S-1 is now considered to be the standard adjuvant therapy for advanced pancreatic cancer. Randomized controlled studies by JASPAC have demonstrated that S-1 is more effective in prolonging survival in patients with advanced pancreatic cancer in 2013. However, the indications due to biomarkers are not reported. Therefore, our aim is to clarify which biomarkers is important in gemcitabine or S-1 as adjuvant therapy for the resectable pancreatic cancer. These results suggest that the cases with TS positive or DPD negative might be predictor for the response to S-1.
|
Report
(4 results)
Research Products
(10 results)
-
[Journal Article] A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer2011
Author(s)
Akimasa Nakao, Hideki Kasuya, Tevfik T. Sahin, Naohiro Nomura, Akiyuki Kanzaki, Makoto Misawa, Takashi Shirota, Suguru Yamada, Tsutomu Fujii, Hiroyuki Sugimoto, Toshio Shikano, Shuji Nomoto, Shin Takeda, Yasuhiro Kodera, Yukihiro Nishiyama
-
Journal Title
Cancer Gene Therapy
Volume: Vol.18 No.3
Pages: 167-175
Related Report
Peer Reviewed
-
-
-
[Presentation] New biological therapeutic drug, oncolytic herpes virus hrR3, with anti-angiogenesis drug, Bevacizumab, against human gastric cancer xenograft model2012
Author(s)
Hideki Kasuya, Gewen Tan, Tevfik T Sahin, Toshio Shikano, Suguru Yamada, Kazuo Yamamura, Tsutomu Fujii, Hiroyuki Sugimoto, Shuji Nomoto, Shin Takeda, Akimasa Nakao, Yasuhiro Kodera
Organizer
IASGO 2012 (22nd World Congress of the International Association of Surgeons, Gastroenterologists and Oncologisrs)
Place of Presentation
Bangkok, Thailand
Year and Date
2012-12-06
Related Report
-
[Presentation] Epithelial to Mesenchymal Transition (EMT) in Pancreatic Cancer2012
Author(s)
Tsutomu Fujii, Suguru Yamada, Masaya Suenaga, Norio Okumura, Daisuke Kobayashi, Chie Tanaka, Goro Nakayama, Hiroyuki Sugimoto, Masahiko Koike, Shuji Nomoto, Michitaka Fujiwara, Shin Takeda, Yasuhiro Kodera
Organizer
The Joint 43rd Meeting of the American Pancreatic Association and the 17th Meeting of the International Association of Pancreatology
Place of Presentation
Miami, Florida
Year and Date
2012-11-02
Related Report
-
[Presentation] 膵癌における上皮間葉系転換 (EMT) と Zeb-1 の臨床的意義の検討2012
Author(s)
山田 豪,藤井 努,奥村徳夫,末永雅也,田中千恵,大橋紀文,中山吾郎,杉本博行,小池聖彦,野本周嗣,藤原道隆,竹田 伸,小寺泰弘
Organizer
第43回日本膵臓学会大会
Place of Presentation
山形 (ホテルメトロポリタン山形)
Year and Date
2012-06-29
Related Report
-
-
-
-
